Investing.com - Financial Markets Worldwide
Open in App

Genscript Biotech Corp (2945)

Hong Kong
Currency in HKD
33.90
0.00(0.00%)
Closed·

2945 Income Statement

Period Ending:
2024
31/12
2025
31/12
Total Revenues
594.49959.53
Total Revenues Growth
+6.07%+61.4%
Cost Of Revenues
322.36406.32
Gross Profit
272.13553.2
Gross Profit Growth
+0.55%+103.29%
Gross Profit Margin %
45.77%57.65%
Other Operating Expenses, Total
262.84297.96
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
+7.53%+13.36%
53.7971.23
209.05226.73
--
Operating Income
9.28255.25
Operating Income Growth
-64.56%+2,649.9%
EBIT Margin %
1.56%26.6%
Net Interest Expenses
21.358.81
Net Interest Expenses Growth
+26.72%-58.74%
Interest Expense, Total
-8.03-17.29
Interest And Investment Income
29.3826.1
Other Non Operating Expenses, Total
-32.52-312.87
EBT, Excl. Unusual Items
-1.89-48.82
Gain (Loss) On Sale Of Assets
--
Other Unusual Items, Total
-45.51-
EBT, Incl. Unusual Items
-170.8-470.53
EBT, Incl. Unusual Items Growth
-201.13%-175.49%
EBT, Incl. Unusual Items Margin
-28.73%-49.04%
Income Tax Expense
2.9861.87
Net Income to Company
2,855.29-532.4
Minority Interest
106.59-0.43
Net Income
2,961.88-532.83
Net Income Growth
+3,202.19%-117.99%
Net Income Margin %
498.22%-55.53%
Preferred Dividend and Other Adjustments
--
Net Income to Common Excl. Extra Items
-67.18-532.83
Basic EPS - Continuing Operations
-0.03-0.25
Basic EPS - Continuing Operations Growth
-115.81%-676.25%
Diluted EPS - Continuing Operations
-0.03-0.25
Diluted EPS - Continuing Operations Growth
-115.81%-676.25%
Basic Weighted Average Shares Outstanding
2,121.292,167.32
Diluted Weighted Average Shares Outstanding
2,178.32,191.99
Dividend Per Share
--
Dividend Per Share Growth
--
EBITDA
70.04317.61
EBITDA Growth
-16.12%+353.49%
EBITDA Margin %
11.78%33.1%
EBIT
9.28255.25
* In Millions of USD (except for per share items)

FAQ

What was Genscript Biotech’s revenue at year end?

At the end of the last reported fiscal year, Genscript Biotech (2945) recorded total revenue of 959.53 million USD.

How much revenue did Genscript Biotech report in the most recent quarter?

In its most recent quarterly earnings report, Genscript Biotech posted revenue of 404.22 million USD.

What was Genscript Biotech’s net income for the year?

For the full year, Genscript Biotech reported net income of -532.83 million USD.

How much net income did Genscript Biotech post in the last quarter?

In the most recent quarter, Genscript Biotech (2945) posted net income of -129.34 million USD.

What was Genscript Biotech’s gross profit for the year?

Gross profit for the year was reported at 553.20 million USD.

How much gross profit did Genscript Biotech generate last quarter?

Genscript Biotech recorded gross profit of 206.71 million USD in its latest quarterly report.

What was Genscript Biotech’s annual operating income?

For the full year, Genscript Biotech (2945) reported operating income of 255.25 million USD.

What was Genscript Biotech’s operating income last quarter?

Quarterly operating income was 49.55 million USD.

What was Genscript Biotech’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at 83.97 million USD.

What was the quarter-over-quarter change in EBITDA for Genscript Biotech?

EBITDA changed by -22.74% million USD compared to the last quarter.

What is Genscript Biotech’s most recent gross profit margin?

The latest reported gross profit margin for Genscript Biotech (2945) is 51.14% million USD.

What is Genscript Biotech’s most recent net income margin?

Net income margin based on recent financials is -32.00% million USD.

What is Genscript Biotech’s most recent EBIT margin?

Genscript Biotech reported an EBIT margin of 12.26% million USD based on current figures.

How did Genscript Biotech’s revenue change compared to the previous quarter?

Revenue changed by -8.29% million USD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Genscript Biotech?

In the latest quarter, gross profit changed by -11.12% million USD from the previous quarter.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.